Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Turning Point Therapeutics, Inc.
Eastern Cooperative Oncology Group
City of Hope Medical Center
Kaiser Permanente
City of Hope Medical Center
Eli Lilly and Company
Var2 Pharmaceuticals
UNC Lineberger Comprehensive Cancer Center
Eli Lilly and Company
GONGCHU Biotechnology Co., Ltd
Sensei Biotherapeutics, Inc.
Gustave Roussy, Cancer Campus, Grand Paris
Esperas Pharma Inc.
Institut du Cancer de Montpellier - Val d'Aurelle
Stanford University
Intensity Therapeutics, Inc.
Mayo Clinic
Rutgers, The State University of New Jersey
Stanford University
Immunophotonics, Inc.
European Organisation for Research and Treatment of Cancer - EORTC
National Cancer Institute (NCI)
pharmaand GmbH
Kineta Inc.
Case Comprehensive Cancer Center
Genzada Pharmaceuticals USA, Inc.
Roswell Park Cancer Institute
MacroGenics
Stanford University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)
Mayo Clinic
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Altor BioScience
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
City of Hope Medical Center
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)